DANCR and glioma: Li and Zhou (2018) also verified that high expression of DANCR might be a poor prognostic factor in glioma patients. Moreover, Ma Y. et al. (2018) found that DANCR promoted cisplatin resistance via activating AXL/PI3K/Akt/NF-κB signaling pathway through competitively binding with miRNAs, including miR-33a-5p, miR-33b-5p, miR-1-3p, miR-206, and miR-613 in glioma.